| Schedule of Segment Reporting Information, by Segment [Table Text Block] |  
|  |  |  |  |  |  |  |  |  |  
|  |  |  |  |  |  |  |  |  |  
|  | Year Ended June 30,  |  
|  | 2022 |      | 2021 |      | 2020 |  
| Net sales: |  |    |  |  |  |  |  |  |  
| Protein Sciences | $ |  832,311 |    | $ |  704,564 |  | $ |  555,352 |  
| Diagnostics and Genomics |   |  274,843 |  |   |  227,744 |  |   |  184,549 |  
| Intersegment |   |  (1,555) |  |   |  (1,276) |  |   |  (1,210) |  
| Consolidated net sales | $ |  1,105,599 |    | $ |  931,032 |  | $ |  738,691 |  
|  |  |  |  |  |  |  |  |  |  
| Operating income: |   |    |  |   |    |  |   |    |  
| Protein Sciences(1) | $ |  377,623 |    | $ |  330,225 |  | $ |  234,929 |  
| Diagnostics and Genomics |   |  48,977 |  |   |  38,425 |  |   |  14,965 |  
| Segment operating income |   |  426,600 |  |   |  368,650 |  |   |  249,894 |  
| Costs recognized on sale of acquired inventory |   |  (1,596) |  |   |  (1,565) |  |   |  — |  
| Amortization of acquisition related intangible assets |   |  (73,054) |  |   |  (64,239) |  |   |  (60,865) |  
| Impact of partially owned consolidated subsidiaries(1) |   |  (2,393) |  |   |  (1,505) |  |   |  — |  
| Gain on escrow settlement |  |  — |  |  |  — |  |  |  7,169 |  
| Acquisition related expenses |   |  19,070 |  |   |  (7,114) |  |   |  (416) |  
| Eminence impairment |  |  (18,715) |  |  |  — |  |  |  — |  
| Stock based compensation, inclusive of employer taxes |   |  (46,401) |  |   |  (51,846) |  |   |  (34,262) |  
| Restructuring costs |   |  (1,640) |  |   |  (142) |  |   |  (87) |  
| Corporate general, selling, and administrative expenses(1) |   |  (5,281) |  |   |  (4,943) |  |   |  (4,015) |  
| Consolidated operating income | $ |  296,590 |    | $ |  237,296 |  | $ |  157,419 |   
|  |  |  |  |  |  |  |  |  |  |  
|  |  | Year Ended June 30,  |  
|  |      | 2022 |      | 2021 |      | 2020 |  
| Consumables revenue - Protein Sciences |  | $ |  646,952 |  | $ |  557,037 |  | $ |  431,052 |  
| Consumables revenue - Diagnostics and Genomics |  |   |  243,922 |  |   |  194,948 |  |   |  171,590 |  
| Total consumable revenue |  | $ |  890,874 |  | $ |  751,985 |  | $ |  602,642 |   
|  |  |  |  |  |  |  |  
|  |  | Year ended June 30,  |  
|  |      | 2022 |        | 2021 |  
| Long-lived assets: |  |  |  |  |  |  |  
| United States and Canada |  | $ |  203,732 |    | $ |  190,501 |  
| Europe |     |   |  16,223 |  |   |  13,949 |  
| Asia |  |   |  3,287 |  |   |  3,457 |  
| Total long-lived assets |  | $ |  223,242 |    | $ |  207,907 |  
| Intangible assets: |  |   |    |  |   |    |  
| United States and Canada |  | $ |  523,536 |    | $ |  594,512 |  
| Europe |  |   |  6,281 |  |   |  9,369 |  
| Asia |  |   |  1,705 |  |   |  12,087 |  
| Total intangible assets |  | $ |  531,522 |    | $ |  615,968 |  |